ADVFN - Advanced Financial Network.
HOME» NASDAQ » M » MYL Stock Price » MYL Stock News

Mylan Inc. Share News

 Mylan Inc. (mm) Stock Price
MYL Stock Price
 Mylan Inc. (mm) Stock Chart
MYL Stock Chart
 Mylan Inc. (mm) Stock News
MYL Stock News
 Mylan Inc. (mm) Company Information
MYL Company Information
 Mylan Inc. (mm) Stock Trades
MYL Stock Trades

Mylan Confirms Endo Suit Over Generic Migraine Drug Application

DOW JONES NEWSWIRES Mylan Inc. (MYL) confirmed Wednesday that it has been sued by Endo Pharmaceuticals Holdings Inc. (ENDP) over its application for approval of a generic drug used to treat acute migraine headaches in adults. Mylan--one of the world's largest generic drug makers--said it believes it is the first company to file a substantially complete application for approval of frovatriptan succinate EQ, a generic version of Frova. The company said it expects to qualify for 180 days of marketing exclusivity upon final approval from the Food and Drug Administration. Mylan, which has had litigation-related charges figure prominently in its recent quarterly results, last month reported second-quarter earnings surged 70% as sales got a lift from a weaker dollar. Shares closed Tuesday at $20.01 and were inactive in recent premarket trade. Through the latest close, the stock is down 5.3% since the start of the year. -By Mia Lamar, Dow Jones Newswires; 212-416-3207; [email protected]

Stock News for Mylan Inc. (MYL)
DateTimeHeadline
02/16/201708:08:00U.S. FDA Accepts Biologics License Application (BLA) for Mylan...
02/14/201713:59:00Mylan Applauds the Generic Pharmaceutical Association's Rebrand...
02/13/201708:46:20Statement of Ownership (sc 13g)
02/10/201710:36:50Statement of Ownership (sc 13g)
02/09/201710:46:47Schedule 13g
02/03/201706:33:00Mylan to Host Investor Day on March 1, 2017 in New York City
02/01/201703:02:00More Headaches for Drugmakers -- WSJ
01/30/201718:51:00Mylan Wins U.S. District Court Ruling Related to Copaxone® 40...
01/25/201714:53:22Amended Statement of Ownership (sc 13g/a)
01/19/201716:27:00Rival to EpiPen Allergy Treatment to Return to Market--Update
01/19/201715:17:00Rival to EpiPen Allergy Treatment to Return to Market
01/12/201717:03:00Cigna Drops Coverage of Mylan's EpiPen for Cheaper Generic...
01/12/201712:49:00Cigna Drops Coverage of Mylan's EpiPen for Cheaper Generic
01/11/201708:00:00U.S. FDA Accepts Biologics License Application (BLA) for Mylan...
01/09/201708:45:00Mylan to Present at the 35th Annual J.P. Morgan Healthcare Conference
01/09/201707:30:00Mylan Acquires Cold-EEZE® Brand to Further Expand OTC Business
01/04/201706:02:06Notice of Effectiveness (effect)
01/03/201717:15:00Prospectus Filed Pursuant to Rule 424(b)(3) (424b3)
01/03/201717:15:00Prospectus Filed Pursuant to Rule 424(b)(3) (424b3)
01/03/201717:09:46Prospectus Filed Pursuant to Rule 424(b)(3) (424b3)

Mylan Inc. and other NASDAQ stock quotes are delayed by at least 20 minutes.
All other stock price and quote data is delayed by at least 15 minutes unless otherwise stated. By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Contact Us | Copyright 1999-2016 ADVFN PLC. | Privacy Policy | Investment Warning | Data accreditations | Investor Relations

ADVFNADVFN ItalyADVFN GermanyADVFN FranceADVFN BrazilADVFN JapanADVFN UKADVFN US